Skip to main content

Advertisement

Table 1 In vivo efficacy of TY-011 against human MGC-803 xenograft

From: Antitumor activity of TY-011 against gastric cancer by inhibiting Aurora A, Aurora B and VEGFR2 kinases

Compound Body weight (g) Tumor volume (mm3) T/C (%) TGI (%) Tumor weight (g) Inhibition rate (%)
Start End Start End
Control 22.1 ± 0.2 22.6 ± 0.2 190.4 ± 6.2 783.7 ± 22.7 / / 0.79 ± 0.07 /
TY-011 (3 mg/kg) 20.8 ± 0.1 21.8 ± 0.1 192.8 ± 7.1 433.6 ± 16.2*** 54.55 59.41 0.28 ± 0.02*** 64.9
TY-011 (6 mg/kg) 20.9 ± 0.1 20.3 ± 0.2 191.2 ± 6.2 168.8 ± 7.1*** 21.82 103.77 0.10 ± 0.01*** 87.7
TY-011 (9 mg/kg) 21.4 ± 0.1 21.7 ± 0.1 189.0 ± 4.9 111.4 ± 3.6*** 14.53 113.09 0.09 ± 0.01*** 89.0
Irinotecan (50 mg/kg) 21.2 ± 0.2 21.4 ± 0.2 191.7 ± 6.7 59.3 ± 6.5*** 8.04 122.31 0.03 ± 0.01*** 96.2
  1. The body weight, tumor volume, T/C values, TGI, tumor weight, and inhibition rate were used to evaluate the tumor response to TY-011 treatment
  2. Data presented are the mean ± SEM. ***p < 0.001 vs. control